Isatuximab in combination with novel agents in RRMM - Master protocol

Trial Identifier: ACT16482
Sponsor: Sanofi
Start Date: January 2021
Primary Completion Date: September 2027
Study Completion Date: April 2028
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AUSTRALIA, New South Wales Wollongong, New South Wales, AUSTRALIA, 2500
AUSTRALIA, Victoria Melbourne, Victoria, AUSTRALIA, 3065
AUSTRALIA, Victoria Richmond, Victoria, AUSTRALIA, 3121
FRANCE Lille, FRANCE, 59037
FRANCE Nantes, FRANCE, 44093
FRANCE Paris, FRANCE, 75015
FRANCE, Washington Paris, Washington, FRANCE, 75651
GERMANY Frankfurt, GERMANY, 60590
GERMANY Lübeck, GERMANY, 23538
GREECE Athens, GREECE, 115 28
GREECE Athens, GREECE, 106 76
ISRAEL Jerusalem, ISRAEL, 9112001
ISRAEL Ramat Gan, ISRAEL, 5262100
ISRAEL Tel Aviv, ISRAEL, 6423906
ITALY, Reggio Emilia Meldola, Reggio Emilia, ITALY, 47014
KOREA, REPUBLIC OF, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 03080
KOREA, REPUBLIC OF, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 06351
KOREA, REPUBLIC OF, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 06591
KOREA, REPUBLIC OF, Seoul-teukbyeolsi Seoul, Seoul-teukbyeolsi, KOREA, REPUBLIC OF, 03722
NORWAY Oslo, NORWAY, 0450
PORTUGAL Coimbra, PORTUGAL, 3000-075
PORTUGAL Porto, PORTUGAL, 4434-502
PUERTO RICO, Puerto Rico Hato Rey, Puerto Rico, PUERTO RICO, 00917
UNITED STATES, Georgia Atlanta, Georgia, UNITED STATES, 30322
UNITED STATES, Illinois Chicago, Illinois, UNITED STATES, 60612
UNITED STATES, Michigan Ann Arbor, Michigan, UNITED STATES, 48109
UNITED STATES, New York Buffalo, New York, UNITED STATES, 14263
UNITED STATES, Ohio Columbus, Ohio, UNITED STATES, 43210